Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
2.39(c) 2.53(c) 2.71(c) 2.75(c) 2.84(c) Last
692 856 958 584 1 076 181 1 790 948 7 606 166 Volume
+3.46% +5.86% +7.11% +1.48% +3.27% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -22,8 M
Net income 2017 -22,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 9,87 M
EBIT 2018 -21,4 M
Net income 2018 -21,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 24,1x
Capitalization 238 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
06/01 Catalyst Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conferen..
05/26 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Departure of Directors..
05/26 CATALYST PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Subm..
05/17 Catalyst Pharmaceuticals to Present at the Antiepileptic Drug and Device Tria..
05/13 CATALYST PHARMACEUTICALS : Receives 2017 Beacon Council Award for Contributions ..
05/12 Catalyst Pharmaceuticals Receives 2017 Beacon Council Award for Contributions..
05/11 CATALYST PHARMACEUTICALS : Announces Poster Presentation of MuSK-MG clinical dat..
05/11 CATALYST PHARMACEUTICALS INC : Investor Network: Catalyst Pharmaceuticals, Inc. ..
05/10 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Other Events
05/10 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/24Catalyst Pharmaceuticals $CPRX Earns News Sentiment Score of 0.54  
06/21$CPRX nice continuation 
06/20$CPRX long setup 
06/19Catalyst Pharmaceuticals $CPRX Receiving Somewhat Critical Media Coverage, Al.. 
06/16Catalyst Pharmaceuticals $CPRX Earning Somewhat Negative Press Coverage, Repo.. 
More tweets
Qtime:16
News from SeekingAlpha
06/07 Catalyst Pharmaceuticals (CPRX) Presents At Jefferies 2017 Global Healthcare ..
05/11 Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q1 2017 Resul..
05/10 Catalyst Pharmaceutical EPS in-line
03/16 HEALTHCARE - TOP 5 GAINERS / LOSERS : 20
03/16 Catalyst Pharmaceutical Partners' (CPRX) CEO Pat McEnany on Q4 2016 Results -..
Advertisement
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Full-screen chart
Technical analysis trends CATALYST PHARMACE...
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 4,56 $
Spread / Average Target 61%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICA..170.48%238
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
More Results